Drug Interactions between allopurinol and Inlyta
This report displays the potential drug interactions for the following 2 drugs:
- allopurinol
- Inlyta (axitinib)
Interactions between your drugs
No interactions were found between allopurinol and Inlyta. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
allopurinol
A total of 427 drugs are known to interact with allopurinol.
- Allopurinol is in the following drug classes: antigout agents, antihyperuricemic agents.
-
Allopurinol is used to treat the following conditions:
- Calcium Oxalate Calculi with Hyperuricosuria
- Cardiothoracic Surgery (off-label)
- Gout
- High Risk Percutaneous Transluminal Angioplasty (off-label)
- Hyperuricemia Secondary to Chemotherapy
- Leishmaniasis (off-label)
- Mania (off-label)
- Reactive Perforating Collangenosis (off-label)
- Urinary Tract Stones (off-label)
Inlyta
A total of 217 drugs are known to interact with Inlyta.
- Inlyta is in the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors.
- Inlyta is used to treat Renal Cell Carcinoma.
Drug and food interactions
allopurinol food
Applies to: allopurinol
Consumer information for this interaction is not currently available.
ADJUST DOSING INTERVAL: The tolerability of allopurinol may be improved by giving it after a meal. Additionally, when the dose is greater than 300 mg, dividing the total daily dose into smaller doses administered more often may be appropriate to help minimize gastrointestinal irritation.
MONITOR: Concomitant use of allopurinol with central nervous system (CNS) depressants, including alcohol, may potentiate adverse effects such as somnolence and sedation.
MANAGEMENT: To improve tolerability, some manufacturers suggest administering allopurinol after a meal. Additionally, if the daily dose is greater than 300 mg, administering allopurinol in divided doses may help reduce gastrointestinal intolerance. Patients should also be counseled to avoid or limit consumption of alcohol and to avoid activities requiring mental alertness such as driving or operating hazardous machinery until they know how the medication affects them.
References
- (2024) "Product Information. Allopurinol (Sandoz) (allopurinol)." Sandoz Pty Ltd
- (2021) "Product Information. Zyloric (allopurinol)." Aspen Pharma Trading Ltd
- (2021) "Product Information. Zyloprim (allopurinol)." AA Pharma Inc, 248178
- (2024) "Product Information. Allopurinol (allopurinol)." Actavis U.S. (Purepac Pharmaceutical Company)
axitinib food
Applies to: Inlyta (axitinib)
Do not consume grapefruit or grapefruit juice during treatment with axitinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of axitinib. This may increase the risk and/or severity of side effects such as high blood pressure, diarrhea, nausea, vomiting, constipation, decreased appetite, weight loss, and rash, itching or peeling of skin on the hands and feet. You may also be more likely to experience less common but more severe side effects such as blood clots (depending on location, can lead to complications such as stroke, heart attack, breathing difficulties, and vision abnormalities); bleeding; liver problems; thyroid problems; tearing (perforation) in the stomach or intestinal wall; and a rare nervous system condition known as reversible posterior leukoencephalopathy syndrome (RPLS). You should seek immediate medical attention if you develop signs and symptoms of these conditions including chest pain or pressure; pain in the arms, back, neck or jaw; swelling; shortness of breath; numbness or weakness on one side of the body; headache; vision changes; seizures, unusual bleeding or bruising; red or black stools; coughing up or vomiting blood or blood clots; and severe stomach or abdominal pain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.